Vascular Biogenics Ltd (VBLT) is CVI Holdings LLC’s 8th Largest Position

CVI Holdings LLC decreased its holdings in Vascular Biogenics Ltd (NASDAQ:VBLT) by 19.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,401,778 shares of the biopharmaceutical company’s stock after selling 338,318 shares during the quarter. Vascular Biogenics comprises 3.0% of CVI Holdings LLC’s investment portfolio, making the stock its 8th largest holding. CVI Holdings LLC owned 3.91% of Vascular Biogenics worth $1,360,000 as of its most recent SEC filing.

Separately, First Republic Investment Management Inc. purchased a new stake in shares of Vascular Biogenics during the 3rd quarter valued at about $438,000. 13.96% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ VBLT opened at $1.66 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.47 and a current ratio of 11.47. The stock has a market cap of $59.56 million, a PE ratio of -4.49 and a beta of -0.14. Vascular Biogenics Ltd has a 12-month low of $0.60 and a 12-month high of $3.10.

Several brokerages have recently issued reports on VBLT. HC Wainwright restated a “buy” rating and set a $3.00 target price on shares of Vascular Biogenics in a research report on Tuesday, January 15th. Chardan Capital restated a “hold” rating and set a $3.00 target price on shares of Vascular Biogenics in a research report on Tuesday, November 20th. Finally, ValuEngine upgraded shares of Vascular Biogenics from a “sell” rating to a “hold” rating in a research report on Thursday, January 3rd.

COPYRIGHT VIOLATION WARNING: “Vascular Biogenics Ltd (VBLT) is CVI Holdings LLC’s 8th Largest Position” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at

About Vascular Biogenics

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.

Further Reading: Technical Analysis of Stocks, How Can It Help

Want to see what other hedge funds are holding VBLT? Visit to get the latest 13F filings and insider trades for Vascular Biogenics Ltd (NASDAQ:VBLT).

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with's FREE daily email newsletter.

Leave a Reply